one-carbon Therapeutics

About one-carbon Therapeutics

Based in Solna, Sweden, One-carbon Therapeutics AB is a preclinical biotechnology company established in 2020. It was co-founded by the Helleday Laboratory, which contributes over two decades of expertise in DNA Damage Response (DDR) biology. The company's scientific foundation is built upon the pioneering work of its founder, Professor Thomas Helleday, who was instrumental in discovering the synthetic lethal concept for treating BRCA mutated cancer with PARP inhibitors.

The company is developing therapeutics to address difficult-to-treat cancers, inflammation, and autoimmune diseases. Its core strategy involves targeting the one-carbon metabolism pathway, which is crucial for DNA synthesis and repair and is often overactive in cancer cells. This approach represents a novel way of attacking the DNA Damage Response, aiming to create treatments that are more selective towards cancer cells while sparing normal ones, thereby reducing side effects commonly associated with chemotherapy and radiotherapy.

One-carbon Therapeutics' lead candidate, TH9619, is a first-in-class small-molecule inhibitor of MTHFD1/2, isoenzymes that regulate one-carbon metabolism and are frequently upregulated in various cancers. The development is guided by advanced biomarkers identified from primary patient tumors to enable a biomarker-driven patient selection process. The company is focused on the late-stage preclinical development of TH9619, with plans to start clinical Phase I trials. The business model centers on advancing its proprietary compounds through the clinical trial process, with an interest in partnering for further clinical and commercial development.